Video
John DeLuca, PhD
At the 2018 CMSC Annual Meeting, Dr. Deluca discusses the role of cognitive rehabilitation in MS.
Conference Coverage
Cladribine Tablets Improve MRI Outcomes in Patients With Highly Active Relapsing-Remitting MS
NASHVILLE—Treatment with cladribine tablets 3.5 mg/kg reduces MRI markers of...
Conference Coverage
What Are Predictors of Mortality in Veterans With MS?
NASHVILLE—Among veterans with multiple sclerosis (MS), excess MS-related mortality is mainly influenced...
Conference Coverage
Compared With Interferon, Fingolimod Improves MRI Outcomes of Pediatric MS
NASHVILLE—In patients with pediatric-onset multiple sclerosis (MS), fingolimod significantly reduces MRI activity and slows brain volume loss for...
Conference Coverage
Can Exercise Improve Vision in Children With MS?
NASHVILLE—Moderate-to-vigorous physical activity is positively associated with retinal nerve fiber layer thickness in children with multiple...
Conference Coverage
More Frequent Dosing of Interferon Beta-1a May Benefit Patients With MS With Breakthrough Disease
NASHVILLE—Patients with multiple sclerosis (MS) with breakthrough disease may benefit from intramuscular interferon beta 1-a treatment twice per...
Conference Coverage
Ocrelizumab’s Benefits on Confirmed Disability Improvement Persist in Open-Label Extension
NASHVILLE—The benefits of ocrelizumab on 24-week confirmed disability improvement, which were demonstrated in two-year, double-blind, controlled...
Video
Global MS trends: A chaotic picture with risk as the central theme
It’s tough to draw firm conclusions from the vastly varied studies assessing epidemiologic patterns of MS around the world, says Dr. Alberto...
Video
Focus on preventing comorbidities in MS, physician urges
NASHVILLE, TENN. – It’s a kind of ‘lifestyle disease’ since other conditions can worsen it, Dr. Allen C. Bowling says, so healthier living is...
Video
New guidelines for gadolinium-based contrast agents take conservative stance
NASHVILLE, TENN. – The agents remain necessary in initial diagnosis and other specific clinical scenarios.
Video
VIDEO: PML prevention is possible, even when treating patients with aggressive MS
NASHVILLE, TENN. – Short treatment periods with natalizumab are possible for patients with aggressive disease, even with JC virus antibody...
Conference Coverage
Can Neurologists Predict a Patient’s Nonadherence to DMTs for MS?
NASHVILLE—Demographic characteristics, comorbidities, and previous treatments can predict intentional and unintentional...
Conference Coverage
How Does the Gut Microbiome Differ in Patients With Relapsing MS Versus Controls?
NASHVILLE—The microbiome composition of patients with multiple sclerosis (MS) may differ significantly from that of healthy...
Conference Coverage
A Mediterranean Diet May Be Associated With Lower Depression and Cognitive Impairment Scores in Patients With MS
Conference Coverage
Ozanimod May Provide Better MS Outcomes Than Interferon Beta
NASHVILLE—Two doses of ozanimod provide greater benefits on annualized relapse rate and MRI end points than interferon beta-1a...
Conference Coverage
Oligoclonal Bands May Predict MS Relapses and Progression
NASHVILLE—Patients with multiple sclerosis (MS) and 10 or more oligoclonal bands (OCBs) in CSF may have significantly more...
Conference Coverage
Rapid Foot-Tapping Task Distinguishes Between MS Subtypes
NASHVILLE—A rapid foot-tapping task can distinguish between healthy controls and people with multiple sclerosis (MS), as well as...
Conference Coverage
-
-
What Are Predictors of Mortality in Veterans With MS? -
-
Can Exercise Improve Vision in Children With MS? -
More Frequent Dosing of Interferon Beta-1a May Benefit Patients With MS With Breakthrough Disease
Multimedia
Question 1 of 5
